1. Home
  2. VRTX vs DE Comparison

VRTX vs DE Comparison

Compare VRTX & DE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • DE
  • Stock Information
  • Founded
  • VRTX 1989
  • DE 1837
  • Country
  • VRTX United States
  • DE United States
  • Employees
  • VRTX N/A
  • DE N/A
  • Industry
  • VRTX EDP Services
  • DE Industrial Machinery/Components
  • Sector
  • VRTX Technology
  • DE Industrials
  • Exchange
  • VRTX Nasdaq
  • DE Nasdaq
  • Market Cap
  • VRTX 115.6B
  • DE 138.0B
  • IPO Year
  • VRTX 1991
  • DE N/A
  • Fundamental
  • Price
  • VRTX $462.13
  • DE $500.98
  • Analyst Decision
  • VRTX Buy
  • DE Buy
  • Analyst Count
  • VRTX 25
  • DE 15
  • Target Price
  • VRTX $509.00
  • DE $515.87
  • AVG Volume (30 Days)
  • VRTX 1.1M
  • DE 1.1M
  • Earning Date
  • VRTX 08-04-2025
  • DE 08-14-2025
  • Dividend Yield
  • VRTX N/A
  • DE 1.29%
  • EPS Growth
  • VRTX N/A
  • DE N/A
  • EPS
  • VRTX N/A
  • DE 20.67
  • Revenue
  • VRTX $11,099,700,000.00
  • DE $45,384,000,000.00
  • Revenue This Year
  • VRTX $10.43
  • DE N/A
  • Revenue Next Year
  • VRTX $10.81
  • DE $7.91
  • P/E Ratio
  • VRTX N/A
  • DE $24.24
  • Revenue Growth
  • VRTX 8.98
  • DE N/A
  • 52 Week Low
  • VRTX $377.85
  • DE $340.20
  • 52 Week High
  • VRTX $519.88
  • DE $533.78
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 49.57
  • DE 44.93
  • Support Level
  • VRTX $460.55
  • DE $504.74
  • Resistance Level
  • VRTX $474.76
  • DE $526.56
  • Average True Range (ATR)
  • VRTX 9.12
  • DE 10.91
  • MACD
  • VRTX -1.34
  • DE 0.18
  • Stochastic Oscillator
  • VRTX 28.52
  • DE 25.86

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About DE Deere & Company

Deere is the world's leading manufacturer of agricultural equipment and a major producer of construction machinery. The company is divided into four reporting segments: production & precision agriculture (PPA), small agriculture & turf (SAT), construction & forestry (CF), and financial services (FS), its captive finance subsidiary. The core PPA business is the largest contributor to sales and profits by far. Geographically, Deere sales are 60% US/Canada, 17% Europe, 14% Latin America, and 9% rest of world. Deere goes to market through a robust dealer network that includes over 2,000 dealer locations in North America with reach into over 100 countries. John Deere financial provides retail financing for machinery to its customers and wholesale financing for dealers.

Share on Social Networks: